Guide
NAD+ injection dosage: how it is dosed and what research has used
NAD+ is sold as a food supplement, so there is no approved dosing schedule. The studies that injected it were small and short; this guide lists what each one gave and explains how to read mg and ml.
By The NAD Team · Reviewed September 2026 · 8 min read
There is no official NAD+ injection dosage: NAD+ is sold as a food supplement, not as a licensed medicine, so there is no approved dosing schedule to quote. Doses are written as milligrams per injection at a set frequency, and the few human studies we could find gave between 100mg and 750mg at a time, into a vein or under the skin, for no more than four days in a row.
What follows is the research record, with no personal dose in it. If you are using our kit, the leaflet in the box is the schedule to follow.
Is there a standard NAD+ dosage?
No, for the reason in the opening paragraph: a food supplement has no approved dose. Amounts quoted by clinics and sellers are their own protocols.
Research has not filled that gap. The authors of a 2026 study of NAD+ drips (Reyna et al.) point out that clinics and wellness settings increasingly offer NAD+ into a vein "despite limited evaluation of safety and effectiveness". The human studies that have given NAD+ by injection or drip are small and short. None of them was designed to find the right dose for anyone: the table further down shows what each one set out to measure.
How NAD+ injection dosage and frequency are written
A dosing schedule has at least two numbers: an amount of NAD+ in milligrams (mg), and a frequency, meaning how often it is given. A schedule should also say how long it runs, in days or weeks, and by which route: under the skin, into a muscle or into a vein. For a liquid there is one more number, the concentration, written as mg per ml. It tells you how much NAD+ is in each millilitre of liquid, and it is the number that links a volume to a dose.
A vial label gives the total amount of NAD+ inside. A vial marked 500mg holds 500mg in all, and the amount in any one injection depends on how much liquid is drawn from it. So an "NAD+ 500 mg injection dosage chart" has to start from the concentration, which is set by whoever made the vial.
The worked example below uses made-up round numbers. They are for the arithmetic only: they are not the strength of our vial, and they are not a suggested dose. Imagine a vial holding 500mg of NAD+ dissolved in 10ml of liquid. Dividing 500mg by 10ml gives a concentration of 50mg per ml. From there the sums run both ways. Half a millilitre of that liquid would hold 25mg, and 100mg would take up 2ml. That last pair of numbers, 100mg in 2ml, is the strength used in the one subcutaneous study in the table below.
If you are reading a schedule you have been given, check that its numbers agree with each other. The volume multiplied by the concentration should equal the stated amount in mg. If they do not match, or the schedule gives a volume with no concentration, ask the supplier or a pharmacist before injecting anything.
NAD+ injection dosage chart: what published studies used
These are the human studies of injected NAD+ whose methods we were able to read and check. Each amount is given as the authors reported it. Other small studies and conference abstracts exist, and we have left out any we could not read in full. The table is a record of research, and none of these amounts is a recommendation.
| Study | Route and amount | How often | Who took part | What it measured |
|---|---|---|---|---|
| Grant et al., 2019 | Into a vein (drip): 750mg in saline over 6 hours, about 2mg a minute | Once | 8 men aged 30 to 55, plus 3 given saline only | NAD+ and its breakdown products in blood and urine |
| Reyna et al., 2026 | Into a vein (drip): 500mg in 500ml of saline, each person setting their own rate | Once a day for 4 days in a row | 6 adults (2 women, 4 men, average age 29) at a US wellness clinic, from records reviewed afterwards | Symptoms during the drip, infusion time, blood pressure, heart rate and blood tests over 30 days |
| Nkrumah-Elie et al., 2026 (preprint) | Under the skin: 100mg in 2ml | Once a day for 3 days in a row | 6 adults aged 40 to 65 with a BMI of 25 to 34.9 and mild fatigue | Safety and how the injections felt |
| Nkrumah-Elie et al., 2026 (preprint) | Into a muscle: 100mg in 2ml | Once a day for 3 days in a row | 4 adults from the same trial | Safety and how the injections felt |
| Nkrumah-Elie et al., 2026 (preprint) | Into a vein (single push): 100mg in 2ml | Once a day for 3 days in a row | 5 adults from the same trial | Safety and how the injections felt |
No NAD+ group in the table had more than eight people, and nobody received NAD+ for more than four days, so there is no human data here on weeks or months of use. Each study also gave everyone in a group the same number of milligrams, regardless of body weight.
The last three rows come from a preprint, which means the paper has not yet been through peer review. The trial was funded by a company that makes nicotinamide riboside, a related ingredient the trial also tested, and several authors work for it. The authors describe their results as "a preliminary safety signal, not a definitive characterization".
NAD+ dosage per day by subcutaneous injection
The injections in our kit are subcutaneous, meaning they go just under the skin, and they are given with a reusable metal auto-injector. This is where the evidence is thinnest.
The only human data on subcutaneous NAD+ we found is the preprint above: six people in a clinic in Alabama, given 100mg once a day for three days. Its authors report that under the skin, NAD+ and nicotinamide riboside "performed comparably" straight after injection and afterwards. No participant in that trial withdrew because of discomfort, and no severe or unexpected adverse events were attributed to either ingredient. The paper covers safety only. The trial listed blood NAD+ measurements among its outcomes, and those are not reported in this paper.
Anyone searching for an NAD+ injection dosage per day, by subcutaneous injection or any other route, will not find one set by research. We found no published human study that gave subcutaneous NAD+ for longer than three days.
What affects how well an NAD+ injection is tolerated?
Into a vein: the infusion rate
The 2026 drip study lists the side effects clinicians and patients commonly report with NAD+ drips, including nausea, sweating, stomach cramping and headache, and notes that anecdotal reports say these side effects "necessitate slow, prolonged infusions" (Reyna et al.). In the clinic records the authors reviewed, all six people given 500mg of NAD+ reported moderate to severe symptoms during the drip: abdominal cramping, diarrhoea, nausea, vomiting, a raised heart rate, throat pain, congestion and chest pressure. Each person controlled their own infusion rate, the drips averaged 97 minutes, and the symptoms stopped as soon as each infusion finished.
The 2019 study ran 750mg over six hours, at about 2mg a minute, and no adverse events were observed (Grant et al.). It also found that at that rate the infused NAD+ was removed from the blood as fast as it went in for at least the first two hours, with no change in plasma NAD+ until after that. The two studies differ in design and setting, so they cannot show how fast is too fast, though the one drip in the table with no adverse events observed was also the slowest.
Under the skin: volume, site, needle and rotation
Beyond the one trial above, what is known about comfort comes from subcutaneous injections of other medicines. A 2019 review of what makes these injections painful lists needle features, the injection site, the volume injected, injection speed, the formulation's osmolality, viscosity and pH, and excipients such as buffers and preservatives (Usach et al.). The review puts the maximum volume generally accepted for one subcutaneous injection at around 1.5ml, and notes that volumes of up to 3ml were tolerated without pain in the abdomen. Thigh injections were rated more painful than injections in the abdomen, while injection speed seemed to make no difference to pain. Shorter, finer needles are generally assumed to hurt less.
Where you inject also needs to move around. NHS guidance from Great Ormond Street Hospital on giving subcutaneous injections says that injecting into the same area all the time causes a fatty lump, called lipohypertrophy, to form. It adds that the lumps are not dangerous in themselves, but medicine is absorbed more slowly through them. The same guidance describes rotating the injection site as one way to make injections less painful and to reduce irritation.
Dosing the NAD+ Kit
Our NAD+ Kit contains a pre-mixed 1000mg vial of NAD+, the reusable metal auto-injector, single-use needles and alcohol wipes. The 1000mg on the label is the total amount of NAD+ in the vial. We do not publish a dosing schedule online.
The leaflet in the kit sets out the schedule for that vial. Follow it, and speak to a doctor first if you are pregnant, breastfeeding, taking prescribed medication or under medical supervision. The kit is not for anyone under 18. Use a fresh single-use needle for every injection, and if you feel unwell after one, stop and get medical advice.
Our page on NAD+ injections at home in the UK covers what is in the kit and how the vial is stored. For what research has reported about side effects, including from routes other than injection, see our guide to NAD+ benefits and side effects.
NAD+ is sold as a food supplement. It is not intended to diagnose, treat, cure or prevent any disease, and nothing in this guide is medical advice.
Questions
Read next
Sources
- Grant R, Berg J, Mestayer R, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience.
- Reyna K, Heinzen G, Patel N, et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging.
- Nkrumah-Elie Y, Kwon J, Simpson S, et al. (2026). Preliminary Safety Analysis of Two Pilot Clinical Trials Involving Injections of Niagen, Nicotinamide Riboside Chloride. medRxiv preprint, not peer reviewed.
- Usach I, Martinez R, Festini T, Peris J-E (2019). Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Advances in Therapy.
- Great Ormond Street Hospital for Children NHS Foundation Trust. Giving subcutaneous injections.
Food supplement. Not a substitute for a varied diet and a healthy lifestyle. Not intended to diagnose, treat, cure or prevent any disease.